======= UBE2E1 ======= == Gene Information == * **Official Symbol**: UBE2E1 * **Official Name**: ubiquitin conjugating enzyme E2 E1 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=7324|7324]] * **UniProt**: [[https://www.uniprot.org/uniprot/P51965|P51965]] * **Interactions**: [[https://thebiogrid.org/search.php?search=UBE2E1&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20UBE2E1|Open PubMed]] * **OMIM**: [[https://omim.org/entry/602916|Open OMIM]] == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. Catalyzes the covalent attachment of ISG15 to other proteins. Mediates the selective degradation of short-lived and abnormal proteins. In vitro also catalyzes 'Lys-48'-linked polyubiquitination. {ECO:0000269|PubMed:16428300, ECO:0000269|PubMed:20061386}. |UQ con| |ISG15 transferase activity| |ISG15-protein conjugation| |histone H2B ubiquitination| |histone monoubiquitination| |ubiquitin conjugating enzyme activity| |histone ubiquitination| |protein K48-linked ubiquitination| |protein monoubiquitination| |anaphase-promoting complex-dependent catabolic process| |ubiquitin ligase complex| |ubiquitin-protein transferase activity| |protein polyubiquitination| |proteasome-mediated ubiquitin-dependent protein catabolic process| |proteasomal protein catabolic process| |histone modification| |covalent chromatin modification| |regulation of mitotic cell cycle phase transition| |regulation of cell cycle phase transition| |ubiquitin-dependent protein catabolic process| |modification-dependent protein catabolic process| |modification-dependent macromolecule catabolic process| |proteolysis involved in cellular protein catabolic process| |cellular protein catabolic process| |regulation of mitotic cell cycle| |protein catabolic process| |protein ubiquitination| |chromatin organization| |regulation of cell cycle process| |protein modification by small protein conjugation| |cellular macromolecule catabolic process| |protein modification by small protein conjugation or removal| |macromolecule catabolic process| |organonitrogen compound catabolic process| |chromosome organization| |regulation of cell cycle| |proteolysis| |ATP binding| |organic substance catabolic process| |cellular catabolic process| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp67|BVD-523 15μM R02 exp67]]|-2.86| |[[:results:exp346|CoCl2 18μM R07 exp346]]|-2.37| |[[:results:exp535|Trimetrexate 0.03μM R08 exp535]]|-2.35| |[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|-2.33| |[[:results:exp64|Nocodazole 0.2μM R02 exp64]]|-2.28| |[[:results:exp292|Menadione 5μM R06 exp292]]|-2.2| |[[:results:exp354|Diepoxybutane 3μM R07 exp354]]|-2.11| |[[:results:exp46|HMS-I1 1μM R01 exp46]]|-2.11| |[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|-2.02| |[[:results:exp59|UMK57 1μM R01 exp59]]|-2.01| |[[:results:exp106|UM131593 0.2μM R03 exp106]]|-2| |[[:results:exp499|LY2090314 0.003μM R08 exp499]]|-1.93| |[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|-1.84| |[[:results:exp107|UMK57 0.6μM R03 exp107]]|-1.79| |[[:results:exp226|Cerivastatin 0.15μM R05 exp226]]|-1.75| |[[:results:exp478|Doxorubicin 0.02μM R08 exp478]]|-1.72| |[[:results:exp30|Rapamycin 10μM R00 exp30]]|1.72| |[[:results:exp11|CCCP 1μM R00 exp11]]|1.73| |[[:results:exp452|Azithromycin 100μM R08 exp452]]|1.87| |[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|2.11| |[[:results:exp29|Rapamycin 1μM R00 exp29]]|2.18| |[[:results:exp407|Thapsigargin 0.005μM R07 exp407]]|2.25| |[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|2.52| |[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|3.02| ^Gene^Correlation^ |[[:human genes:p:pcgf1|PCGF1]]|0.581| |[[:human genes:r:ring1|RING1]]|0.565| |[[:human genes:i:ikzf2|IKZF2]]|0.551| |[[:human genes:b:bcor|BCOR]]|0.518| |[[:human genes:p:pou2af1|POU2AF1]]|0.5| |[[:human genes:c:cdk8|CDK8]]|0.45| |[[:human genes:n:nufip2|NUFIP2]]|0.43| |[[:human genes:g:glyr1|GLYR1]]|0.416| |[[:human genes:a:apex2|APEX2]]|0.408| |[[:human genes:z:znf217|ZNF217]]|0.406| Global Fraction of Cell Lines Where Essential: 0/726 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/25| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/15| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/14| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/7| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 18306 * **Expression level (log2 read counts)**: 5.77 {{:chemogenomics:nalm6 dist.png?nolink |}}